SCHEMBL510056

SCHEMBL510056

CCC1(CC)CNCCN1CCN

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.32
SOS2 Q07890 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27553313 0.86 SOS1 (0.31) SOS1SOS2
SCHEMBL10893120 0.83 ALOX15 (0.30)
SCHEMBL6838356 0.80 TSHR (0.35) SOS1SOS2
SCHEMBL28153211 0.80 GNAO1 (0.36) SOS1SOS2
SCHEMBL6380836 0.77 SOS1 (0.34) SOS1SOS2
Bromide SCHEMBL6291796 0.76 GNAO1 (0.36)
SCHEMBL9000042 0.75 ALOX15 (0.32) SOS1SOS2
Piperazine SCHEMBL28225897 0.74 SOS1 (0.32) SOS1SOS2
SCHEMBL7026604 0.74 SOS1 (0.33) SOS1SOS2
SCHEMBL28142685 0.74 SOS1 (0.47) SOS1SOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028979-A1 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS ASTRAZENECA AB (SE) 2012-02-02 US disclosed
EP-1593701-A1 Curable resin composition Ajinomoto Co., Inc. (JP) 2005-11-09 EP disclosed
EP-0950677-B1 Curable resin composition AJINOMOTO KK (JP) 2005-10-19 EP disclosed
US-6482899-B2 LATENCY CURING AGENTS; STORAGE STABILITY AJINOMOTO CO., INC. (JP) 2002-11-19 US disclosed
US-20020010287-A1 Latency curing agents; storage stability AJINOMOTO CO., INC. (JP) 2002-01-24 US disclosed
EP-0950677-A2 Curable resin composition Ajinomoto Co., Inc. (JP) 1999-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028979-A1 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS TLR5, TLR2, PIR SOS1 2845/4885SOS2 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.